AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32795330 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 30
Study 34616116 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective percutaneous myofascial lengthening (SPML) procedure and 9-month functional strengthening physiotherapy programme
Number of subjects: 52
Study 34616116 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 52
Study 35254443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 37
Study 35254443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 35974018 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model based on physical examination and laboratory tests
Number of subjects: 8861
Study 33307235 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.25% NaOCl with 17% EDTA and ECL (group 4)
Number of subjects: 40
Study 33307235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol based propolis (group 2)
Number of subjects: 40
Study 33307235 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoactivated disinfection (PAD) (group 1)
Number of subjects: 40
Study 33307235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (group 3)
Number of subjects: 40
Study 36073014 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (eicosapentaenoic acid and docosahexaenoic acid)
Number of subjects: 225
Study 36073014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 35895381 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (360 mg) + gemcitabine and cisplatin (days 1 and 8 every 3 weeks for 6 months) followed by nivolumab (240 mg every 2 weeks)
Number of subjects: 75
Study 35895381 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks) + ipilimumab (1 mg/kg every 6 weeks)
Number of subjects: 75
Study 32880227 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization Training for Adolescent Refugees with Trauma Induced Disorders
Number of subjects: 46
Study 32880227 — intervention group
Group type: COMPARATOR
Intervention: Waiting control condition
Number of subjects: 46
Study 35578360 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin (two doses on days 1 and 8)
Number of subjects: 200
Study 35578360 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous antibiotic therapy (4–8 weeks)
Number of subjects: 200
Study 35578360 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 200
Study 34892404 — intervention group
Group type: EXPERIMENTAL
Intervention: GREEN vPPG method
Number of subjects: 10
Study 34892404 — intervention group
Group type: EXPERIMENTAL
Intervention: POS vPPG method
Number of subjects: 10
Study 34892404 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA vPPG method
Number of subjects: 10
Study 34892404 — intervention group
Group type: EXPERIMENTAL
Intervention: CHROM vPPG method
Number of subjects: 10
Study 34892404 — intervention group
Group type: EXPERIMENTAL
Intervention: Averages of the green color intensity
Number of subjects: 10
Study 34892404 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric hand grip exercise and leg ischemia
Number of subjects: 10
Study 32546180 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS notification prior to sending questionnaires
Number of subjects: 1394
Study 32546180 — intervention group
Group type: COMPARATOR
Intervention: No SMS notification
Number of subjects: 1394
Study 32546180 — intervention group
Group type: EXPERIMENTAL
Intervention: £10 voucher sent with the invitation letter for the primary follow‐up visit at 24 months
Number of subjects: 1394
Study 32546180 — intervention group
Group type: COMPARATOR
Intervention: £10 voucher given at the visit
Number of subjects: 1394
Study 33982267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 0.75% BID
Number of subjects: 0
Study 33982267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 1.5% BID
Number of subjects: 0
Study 33982267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream (any strength)
Number of subjects: 0
Study 35332558 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab 300 mg intravenous dose administered on Day 1 and Day 15 and every 6 months thereafter
Number of subjects: 0
Study 35332558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33735712 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (1.6 gr loading, 1.8 gr daily)
Number of subjects: 380
Study 33735712 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir (800/200 mg daily)
Number of subjects: 380
Study 33735712 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 380
Study 33735712 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir
Number of subjects: 380
Study 32040222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 151
Study 32040222 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 151
Study 36377764 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted community health worker (CHW) intervention
Number of subjects: 243908
Study 36377764 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 243908
Study 36147433 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum (QL) block
Number of subjects: 80
Study 36147433 — intervention group
Group type: COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Number of subjects: 80
Study 35748451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonoid olive oil
Number of subjects: 30
Study 35748451 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 30
Study 34482574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of omega-3 fatty acids (300 mg daily) and vitamin D3 (50,000 IU weekly)
Number of subjects: 146
Study 34482574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 146
Study 34482574 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU weekly)
Number of subjects: 146
Study 34482574 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids supplementation (300 mg daily)
Number of subjects: 146
Study 32788052 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ED (ED+ group)
Number of subjects: 123
Study 32788052 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (ED- group)
Number of subjects: 123
Study 34814899 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level diabetes management intervention (including group education sessions on diabetes management, physical activity, and diet/nutrition)
Number of subjects: 886
Study 34814899 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level diabetes management intervention
Number of subjects: 886
Study 34814899 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 886
Study 32334551 — intervention group
Group type: EXPERIMENTAL
Intervention: 42.5 g of almonds per day
Number of subjects: 0
Study 32334551 — intervention group
Group type: COMPARATOR
Intervention: No almond consumption
Number of subjects: 0
Study 33412515 — intervention group
Group type: EXPERIMENTAL
Intervention: Factually correct blog article
Number of subjects: 141
Study 33412515 — intervention group
Group type: COMPARATOR
Intervention: Factually incorrect blog article
Number of subjects: 141
Study 32057842 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie sweetener (LCS) sweetened fruit squash drinks
Number of subjects: 155
Study 32057842 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 155
Study 32057842 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (LCS-sweetened) cola
Number of subjects: 155
Study 32057842 — intervention group
Group type: COMPARATOR
Intervention: Carbonated water
Number of subjects: 155
Study 32057842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-containing cola
Number of subjects: 155
Study 36124078 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a surgical mask
Number of subjects: 35
Study 36124078 — intervention group
Group type: COMPARATOR
Intervention: Not wearing a surgical mask
Number of subjects: 35
Study 32108326 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-field lymphadenectomy
Number of subjects: 400
Study 32108326 — intervention group
Group type: COMPARATOR
Intervention: Two-field lymphadenectomy
Number of subjects: 400
Study 35725950 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior Meatus Antrostomy (IMA) with basal mucosa electrocoagulation
Number of subjects: 107
Study 35725950 — intervention group
Group type: COMPARATOR
Intervention: Middle Meatus Antrostomy (MMA)
Number of subjects: 107
Study 34153248 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus nerve block
Number of subjects: 24
Study 34153248 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia with local infiltration
Number of subjects: 24
Study 35130836 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 1149
Study 35130836 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 1149
Study 35130836 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab (pooled)
Number of subjects: 1149
Study 35130836 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab (≥75% MRR)
Number of subjects: 1149
Study 35130836 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab (≥50-<75% MRR)
Number of subjects: 1149
Study 35130836 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 1149
Study 32400122 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet/Anticoagulant therapy
Number of subjects: 482
Study 32400122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest platelet quartile (platelet count <187)
Number of subjects: 482
Study 32400122 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet/Anticoagulant therapy in lowest platelet quartile
Number of subjects: 482
Study 32400122 — intervention group
Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 482
Study 35616948 — intervention group
Group type: COMPARATOR
Intervention: Supine position RT (50 Gy in 25 fractions or hypofractionation of 42.5 Gy in 16 fractions)
Number of subjects: 357
Study 35616948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position RT (50 Gy in 25 fractions or hypofractionation of 42.5 Gy in 16 fractions)
Number of subjects: 357
Study 34003456 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted radical vaginal hysterectomy (LARVH)
Number of subjects: 261
Study 34003456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginally assisted laparoscopic or robotic radical hysterectomy (VALRRH)
Number of subjects: 261
Study 34003456 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesometrial resection (TMMR)
Number of subjects: 261
Study 34003456 — intervention group
Group type: COMPARATOR
Intervention: Control group (gynecological clinics)
Number of subjects: 261
Study 34003456 — intervention group
Group type: COMPARATOR
Intervention: Control group (urogynaecological patients)
Number of subjects: 261
Study 33725464 — intervention group
Group type: EXPERIMENTAL
Intervention: Greek yogurt
Number of subjects: 40
Study 33725464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 40
Study 33725464 — intervention group
Group type: COMPARATOR
Intervention: 2% fat milk
Number of subjects: 40
Study 33725464 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cortisol
Number of subjects: 40
Study 33087047 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (human) - four vials daily for 3 days
Number of subjects: 59
Study 33087047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 33087047 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 59
Study 33860928 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for modelling test-treatment pathways in economic evaluations of PM
Number of subjects: 0
Study 33860928 — intervention group
Group type: COMPARATOR
Intervention: Non-randomised controlled trial data
Number of subjects: 0
Study 33860928 — intervention group
Group type: EXPERIMENTAL
Intervention: Parameterisation of structural uncertainty
Number of subjects: 0
Study 33860928 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of perspective and discounting
Number of subjects: 0
Study 33860928 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of premature survival data
Number of subjects: 0
Study 33860928 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of additional value elements
Number of subjects: 0
Study 33860928 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and clinician compliance
Number of subjects: 0
Study 33860928 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed entry agreements
Number of subjects: 0
Study 35654659 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus Best Supportive Care (BSC)
Number of subjects: 700
Study 35654659 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC) alone
Number of subjects: 700
Study 35654659 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus BSC
Number of subjects: 700
Study 33210444 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 400 μg
Number of subjects: 11
Study 33210444 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 200 μg
Number of subjects: 11
Study 33210444 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 200 μg for seven consecutive days
Number of subjects: 11
Study 33210444 — intervention group
Group type: COMPARATOR
Intervention: Combined salmeterol and α-hydroxysalmeterol urine threshold
Number of subjects: 11
Study 32483079 — intervention group
Group type: COMPARATOR
Intervention: Normal attire (baseline)
Number of subjects: 108
Study 32483079 — intervention group
Group type: EXPERIMENTAL
Intervention: Full PPE
Number of subjects: 108
Study 33891194 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m2 on day one and eight of each 21-day cycle)
Number of subjects: 58
Study 33891194 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician’s choice (TPC) including paclitaxel, docetaxel, nab-paclitaxel or vinorelbine
Number of subjects: 58
Study 33891194 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician’s choice (TPC)
Number of subjects: 58
Study 33891194 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 58
Study 32880655 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Adenotonsillectomy (AT)
Number of subjects: 453
Study 32880655 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting with supportive care
Number of subjects: 453
Study 35446078 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 338
Study 35446078 — intervention group
Group type: COMPARATOR
Intervention: Duluth Model
Number of subjects: 338
Study 33849853 — intervention group
Group type: EXPERIMENTAL
Intervention: Footprints to Better Balance (FBB)
Number of subjects: 40
Study 33849853 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 32857051 — intervention group
Group type: EXPERIMENTAL
Intervention: Curry solution (distilled water with curry powder containing turmeric)
Number of subjects: 100
Study 32857051 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee solution
Number of subjects: 100
Study 32857051 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 100
Study 32857051 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine solution
Number of subjects: 100
Study 32857051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea solution
Number of subjects: 100
Study 34520728 — intervention group
Group type: EXPERIMENTAL
Intervention: SpeakOut intervention
Number of subjects: 520
Study 34520728 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 520
Study 33855883 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic horseback riding (THR) program for 6 weeks
Number of subjects: 20
Study 35754198 — intervention group
Group type: EXPERIMENTAL
Intervention: collagen plug with cyano‐acrylate (CPC)
Number of subjects: 72
Study 35754198 — intervention group
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin (PRF) + sutures
Number of subjects: 72
Study 35754198 — intervention group
Group type: EXPERIMENTAL
Intervention: palatal stent only (PS)
Number of subjects: 72
Study 35754198 — intervention group
Group type: COMPARATOR
Intervention: collagen plug + sutures (CPS)
Number of subjects: 72
Study 33145841 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-303 3 mg
Number of subjects: 0
Study 33145841 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-303 6 mg
Number of subjects: 0
Study 33145841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33145841 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-303 (3 mg and 6 mg)
Number of subjects: 0
Study 33870433 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (2.6‐6.4 kg/m2)
Number of subjects: 340
Study 33870433 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (2.6‐6.4 kg/m2) in women
Number of subjects: 340
Study 33870433 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance (± 0.5 kg/m2)
Number of subjects: 340
Study 32163797 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based peer-support program 'Supporting a First-time Mother'
Number of subjects: 0
Study 32163797 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36241388 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sleeve gastroplasty (ESG)
Number of subjects: 36
Study 36241388 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle interventions (LS)
Number of subjects: 36
Study 34320651 — intervention group
Group type: EXPERIMENTAL
Intervention: IM‐MS lymph node irradiation
Number of subjects: 4004
Study 34320651 — intervention group
Group type: COMPARATOR
Intervention: No IM‐MS lymph node irradiation
Number of subjects: 4004
Study 32164777 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined educational and electronic reminder system
Number of subjects: 0
Study 32164777 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36307874 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tibial nerve stimulation using the Geko™ device, self-administered at home twice per week for 30 minutes over 3 months.
Number of subjects: 0
Study 36307874 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group).
Number of subjects: 0
Study 34529931 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab maintenance (16 mg/kg intravenously every 8 weeks for 2 years)
Number of subjects: 886
Study 34529931 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 886
Study 34529931 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab maintenance
Number of subjects: 886
Study 32162946 — intervention group
Group type: EXPERIMENTAL
Intervention: Prekindergarten mathematics curriculum
Number of subjects: 0
Study 32162946 — intervention group
Group type: COMPARATOR
Intervention: Nonequivalent comparison group design (NECGD) combining local comparison group, pretest measure, and 19 covariates
Number of subjects: 0
Study 35483979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 1462
Study 35483979 — intervention group
Group type: COMPARATOR
Intervention: Bempedoic acid (initiated after placebo)
Number of subjects: 1462
Study 35483979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid (130 weeks)
Number of subjects: 1462
Study 35483979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid (78 weeks)
Number of subjects: 1462
Study 33564016 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab
Number of subjects: 132
Study 33564016 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 132
Study 35105570 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg daily for 3 days before surgery and 0.5 mg daily for 5 days after surgery)
Number of subjects: 132
Study 35105570 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same schedule as colchicine)
Number of subjects: 132
Study 33689854 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiation therapy with carbogen (98% O2; 2% CO2) and nicotinamide (CON)
Number of subjects: 333
Study 33689854 — intervention group
Group type: COMPARATOR
Intervention: Radical radiation therapy alone (RT)
Number of subjects: 333
Study 33689854 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiation therapy with CON in patients with tumor necrosis
Number of subjects: 333
Study 33689854 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiation therapy with CON in patients with high hypoxia gene score
Number of subjects: 333
Study 33689854 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiation therapy with CON in patients with basal molecular subtype
Number of subjects: 333
Study 93092255 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellferon (lymphoblastoid interferon-alpha)
Number of subjects: 801
Study 93092255 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 801
Study 35934281 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) with an eating window ≤10 h/day
Number of subjects: 62
Study 35934281 — intervention group
Group type: COMPARATOR
Intervention: Habitual prolonged eating window (HABIT) with an eating window ≥14 h/day
Number of subjects: 62
Study 35934281 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 62
Study 33559428 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver needle heat conduction therapy + loxoprofen sodium patch (combination group)
Number of subjects: 92
Study 33559428 — intervention group
Group type: COMPARATOR
Intervention: Loxoprofen sodium patch (loxoprofen group)
Number of subjects: 92
Study 32239291 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0
Study 32410059 — intervention group
Group type: EXPERIMENTAL
Intervention: Vereos SiPM PET
Number of subjects: 30
Study 32410059 — intervention group
Group type: COMPARATOR
Intervention: D690 PMT PET
Number of subjects: 30